Skip to content

Effect of Er: Yag Laser in the treatment of mild to moderate stress incontinence

Effect of Er: Yag Laser in the treatment of mild to moderate stress incontinence

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060722
Enrollment
Unknown
Registered
2022-06-09
Start date
2022-06-13
Completion date
Unknown
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

incontinence

Interventions

Group A:Er:YAG laser treatment
Group B:Biofeedback electrical stimulation

Sponsors

Pudong New Area Gongli Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Women aged 18 years or older; 2. Mild and moderate patients clinically diagnosed as simple stress urinary incontinence (1h pad test grading method); 3. Those who agree to participate in the clinical trial and sign the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Patients who have undergone pelvic surgery or urinary incontinence surgery; 2. Patients with urge incontinence or filling incontinence or true incontinence or severe stress incontinence; 3. Patients without sexual life history; 4. Bladder tumors or patients who have received radiation therapy; 5. Patients with untreated urinary tract infection or bladder infection; 6. Patients with vesico-vaginal fistula; 7. Patients with vaginal cavity, vaginal opening or vestibular injury; 8. Patients diagnosed with endometriosis; 9. Patients with pelvic organ prolapse grade >= II (according to POP-Q); 10. Patients with stool incontinence; 11. Patients with vaginal bleeding of unknown causes or cervical lesions (such as erosion); 12. Severe hepatic and renal dysfunction (ALT > normal upper limit 3 times; Creatinine > 225 umol/L); 13. The disease may cause difficulty in treatment and evaluation (e.g.sepsis, bacteremia, toxemia, severe metabolic disease, cancer metastasis, mental illness, etc.); 14. Having other conditions that could make the trial difficult or significantly shorten the patients' life expectancy(< 1 year), such as cancer, liver disease, cardiac insufficiency, or a life expectancy of less than 12 months; 15. Pregnant and lactating women, or those with family planning; 16. Patients with poor compliance, unwilling or unable to complete treatment and follow-up plans; 17. Patients who are participating in clinical trials of other drugs or medical devices; 18. Patients considered unsuitable for inclusion by other investigators.

Design outcomes

Primary

MeasureTime frame
effectiveness;

Secondary

MeasureTime frame
Number of urinary incontinence;International consultation on incontinence questionnaire-short form;Incontinence Impact Questionnaire-7;Evaluation of the performance of Er: YAG laser therapy system;Visual analogue scale;Evaluation of patient satisfaction;

Countries

China

Contacts

Public ContactJianwei Lyu

Pudong New Area Gongli Hospital

ljwass2020@163.com+86 13816694688

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026